Moderna (MRNA) continues to expect potential approval of its investigational individualized neoantigen therapy, or INT, by 2027, President Stephen Hoge said at an investor conference Wednesday according to a FactSet transcript.
The investigational therapy, which is being developed in partnership with Merck (MRK), is being evaluated in a phase 3 trial that is fully enrolled.
"We're cautiously optimistic that 2027 is right on path," Hoge said, according to the transcript.
Hoge said Moderna and Merck have not yet guided to pricing, but he said they believe INT could become a large revenue opportunity that could grow quickly as the company expands the indications.
Hoge also said the company is moving forward with phase 3 trials of its bird flu vaccine in the US. "We still believe that that's prudent (to have countermeasures) from a public health perspective," Hoge said, according to the transcript.
Shares of Moderna were up more than 5% in recent trading.
Price: 31.99, Change: +1.62, Percent Change: +5.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.